Marked anti-tumor effects of CD8⁺CD62L⁺ T cells from melanoma-bearing mice

References

• Ben-Sasson SZ, Hogg A, Hu-Li J, et al. (2013). IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med, 210, 491–502
   PubMed Web of Science ®Google Scholar
• Bixby LM, Tarleton RL. (2008). Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol, 181, 2644–50
   PubMed Web of Science ®Google Scholar
• Brinkman CC, Rouhani SJ, Srinivasan N, Engelh VH. (2013). Peripheral tissue homing receptors enable T Cell entry into lymph nodes and affect the anatomical distribution of memory cells. J Immunol, 191, 2412–24
   Google Scholar
• Carriére M, Lacabaratz C, Kök A, et al. (2014). HIV “elite controllers” are characterized by a high frequency of memory CD8+CD73+ T cells involved in the antigen-specific CD8+ T-cell response. J Infect Dis, 209, 1321--30
   PubMed Web of Science ®Google Scholar
• Casati A, Varghaei-Nahvi A, Feldman SA, et al. (2013). Clinical-scale selection and viral transduction of human naive and central memory CD8(+) T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother, 62, 1563–73
   Google Scholar
• Cianci R, Iacopini F, Petruzziello L, et al. (2009). Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol, 44, 108–15
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer, 3, 666–75
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Palmer DC, et al. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest, 115, 1616–26
   PubMed Web of Science ®Google Scholar
• Geginat J, Lanzavecchia A, Sallusto F. (2003). Proliferation and differentiation potential of human CD8(+) memory T-cell subsets in response to antigen or homeostatic cytokines. Blood, 101, 4260–6
   PubMed Web of Science ®Google Scholar
• Giannandrea M, Yee M, O’Reilly MA, Lawrence BP. (2012). Memory CD8(+) T cells are sufficient to alleviate impaired host resistance to Influenza A virus infection caused by neonatal oxygen supplementation. Clin Vaccine Immunol, 19, 1432–41
   Google Scholar
• Göthert JR, Eisele L, Klein-Hitpass L, et al. (2013). Expanded CD8(+) T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype. Cancer Immunol Immunother, 62, 1697–709
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Borman ZA, Gattinoni L, et al. (2011). Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 117, 808–14
   PubMed Web of Science ®Google Scholar
• Iancu EM, Gannon PO, Laurent J, et al. (2013). Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One, 8, 0078686
   Google Scholar
• Kausche S, Wehler T, Schnurer E, et al. (2006). Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Cancer Res, 66, 11447–54
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Venturi V, Field K, et al. (2006). Early establishment of diverse T cell receptor profiles for influenza-specific CD8(+)CD62L(hi) memory T cells. Proc Natl Acad Sci USA, 103, 9184–9
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. (2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA, 102, 9571–6
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, et al. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4, 844–947
   PubMed Web of Science ®Google Scholar
• Lee G, Ge B. (2010). Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor. Cancer Immunol Immunother, 59, 1011–19
   PubMedGoogle Scholar
• Liao Y, Ou J, Deng P. (2013). Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. Med Oncol, 30, 727
   Google Scholar
• Matsuki F, Saegusa J, Miyamoto Y, et al. (2013). CD45RA-Foxp3(high) activated/effector regulatory T cells in the CCR7+CD45RA-CD27+CD28+central memory subset are decreased in peripheral blood from patients with rheumatoid arthritis. Biochem Biophys Res Commun, 438, 778–83
   Google Scholar
• Miller CH, Graham L, Bear HD. (2010). Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol, 11, 54
   Google Scholar
• Mills PJ, Goebel M, Rehman J. (2000). Leukocyte adhesion molecule expression and T cell naive/memory status following isoproterenol infusion. J Neuroimmunol, 102, 137–44
   PubMed Web of Science ®Google Scholar
• Mills PJ, Karnik RS, Dillon E. (1997). L-selectin expression affects T-cell circulation following isoproterenol infusion in humans. Brain Behav Immun, 11, 333–42
   Google Scholar
• Monserrat J, de Pablo R, Reyes E, et al. (2009). Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care, 13, R26
   PubMed Web of Science ®Google Scholar
• Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. (1986). Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res, 46, 4109–15
   PubMed Web of Science ®Google Scholar
• Obar JJ, Lefrancois L. (2010). Memory CD8+ T cell differentiation. Ann NY Acad Sci, 1183, 251–66
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Katagiri S, Tauchi T, et al. (2012). Increased natural killer cells and decreased CD3+CD8+CD62L+T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol, 157, 254–6
   PubMed Web of Science ®Google Scholar
• Ohyashiki M, Ohyashiki JH, Hirota A, et al. (2011). Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naive T lymphocytes. Immun Ageing, 8, 11
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med, 198, 569–80
   PubMed Web of Science ®Google Scholar
• Paiardini M, Cervasi B, Albrecht H, et al. (2005). Loss of CD127 expression defines an expansion of effector CD8(+) T cells in HIV-infected individuals. J Immunol, 174, 2900–9
   PubMed Web of Science ®Google Scholar
• Pardoll DM. (2002). Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol, 2, 227–38
   PubMed Web of Science ®Google Scholar
• Perez CJ, Nemet D, Mills PJ, et al. (2001). Effects of laboratory versus field exercise on leukocyte subsets and cell adhesion molecule expression in children. Eur J Appl Physiol, 86, 34–9
   Google Scholar
• Radvanyi LG, Bernatchez C, Zhang M, et al. (2012). Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res, 18, 6758–70
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol, 21, 233–40
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res, 17, 4550–7
   PubMed Web of Science ®Google Scholar
• Sacre K, Carcelain G, Cassoux N, et al. (2005). Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med, 201, 1999–2010
   PubMedGoogle Scholar
• Seder RA, Ahmed R. (2003). Similarities and differences in CD4(+) and CD8(+) effector and memory T cell generation. Nat Immunol, 4, 835–42
   PubMed Web of Science ®Google Scholar
• Sikora A, Koziol-Montewka M, Ksiazek A, et al. (2013). Assessment of cytokine release after in vitro stimulation of whole blood with legionella pneumophila in immunocompromised patients. Immunol Invest, 42, 1–17
   Web of Science ®Google Scholar
• Stemberger C, Huster KM, Koffler M, et al. (2007). A single naive CD8(+) T cell precursor can develop into diverse effector and memory subsets. Immunity, 27, 985–97
   PubMed Web of Science ®Google Scholar
• Vescovini R, Fagnoni FF, Telera AR, et al. (2013). Naive and memory CD8 T cell pool homeostasis in advanced aging: Impact of age and of antigen-specific responses to cytomegalovirus. Age, 36, 625–40
   Google Scholar
• Wang Z, Li P, Xu Q, et al. (2013). Potent antitumor activity generated by a novel tumor specific cytotoxic T cell. PLoS One, 8, e66659
   Google Scholar
• Wu RC, Hwu P, Radvanyi LG. (2012a). New insights on the role of CD8(+)CD57(+) T-cells in cancer. Oncoimmunology, 1, 954–6
   PubMed Web of Science ®Google Scholar
• Wu RC, Liu S, Chacon JA, et al. (2012b). Detection and characterization of a novel subset of CD8(+)CD57(+) T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res, 18, 2465–77
   Google Scholar
• Yee C, Thompson JA, Byrd D, et al. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA, 99, 16168–73
   PubMed Web of Science ®Google Scholar
• Zheng M, Xing C, Xiao H, et al. (2014). Interaction of CD5 and CD72 is involved in regulatory T and B cell homeostasis. Immunol Invest, 20, 1–12
   Google Scholar
• Zheng YN, Yu HP, Chen X, et al. (2012). Inhibition of lipopolysaccharide-induced myeloid-derived suppressor cells in the proliferation of spleen T lymphocytes. Zhonghua Yi Xue Za Zhi, 92, 1702–5
   Google Scholar